2. Academic Validation
  3. Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression

Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression

  • Front Neurol. 2022 Mar 18:13:861843. doi: 10.3389/fneur.2022.861843.
Hongmin Li 1 2,  Zhaofu Sheng 1 2,  Suliman Khan 1 2,  Ruiyi Zhang 1 2,  Yang Liu 1 2,  Yan Zhang 1 2,  V Wee Yong 3 4,  Mengzhou Xue 1 2
Affiliations

Affiliations

  • 1 The Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • 2 The Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China.
  • 3 Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • 4 Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
PMID: 35370878 DOI: 10.3389/fneur.2022.861843
Abstract

Matrix Metalloproteinases (MMPs) are physiologically expressed in the central nervous system in neurons, astrocytes and microglia, and their aberrant elevation contributes to a number of diseases. Amongst the MMP members, MMP-9 has generated considerable attention because of its possible involvement in inflammatory responses, blood-brain barrier permeability, the regulation of perineuronal nets, demyelination, and synaptic long-term potentiation. Emerging evidence indicate an association between MMP-9 and the syndrome of depression. This review provides an updated and comprehensive summary of the probable roles of MMP-9 in depression with an emphasis on the mechanisms and potential of MMP-9 as a biomarker of depression.

Keywords

contributor; depression; matrix metalloproteinase 9 (MMP-9); minocycline; neuroplasticity.

Figures